Dimerix CEO speaks with Proactive at the ASX SMIDcaps Conference

Dimerix CEO Dr Nina Webster talked with Proactive at the ASX Small and Mid-Cap Conference about its work in kidney disease and what $34 million in funding means for its clinical milestones. Dimerix Limited (ASX: DXB) is a clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases with significant unmet medical need. The company’s lead program, DMX-200, is currently in Phase 3 clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, Dimerix is advancing a Phase 2 program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. With a growing network of five commercial partners supporting global development and future market access, Dimerix is committed to expanding its reach and delivering innovative treatments to as many patients as possible worldwide while creating long-term value for shareholders. #DimerixLimited #ProactiveInvestors #DrNinaWebster #PharmaceuticalDevelopment #ClinicalTrials